Skip to main content
Premium Trial:

Request an Annual Quote

Genicon, Novartis Genomics Institute Launch Broad Genomic Partnership

NEW YORK, Nov. 2 — Genicon Sciences has closed a deal to allow the Genomics Institute of the Novartis Research Foundation to use its proprietary Resonance Light Scattering technology, according to Genicon. 

The partners will cooperatively develop and commercialize the technology, which Genicon has designed for stable, highly sensitive signal generation and detection in a range of molecular assays.

By the terms of the deal, San Diego, Calif.-based Genicon also gets certain rights to GNF  microarray technologies, which the company will use to further develop their platform for use in mouse antibody assays and protein microarray kits.

The R&D partnership will be pooled so that each partner pays for its own research costs, and each retains rights to developments in its own products, said a company spokesperson. Under this arrangement, Genicon will retain rights for assay development, and GNS will maintain commercial drug development rights.

Other financial details of the partenrship, originally announced o Thursday, were not disclosed. 

According to Genicon, their RLS technique is highly specific and up to 1 million times more sensitive than fluorescence signaling technology, making it ideal for applications in gene sequencing, immunohistology and gene expression studies.

The company, which is privately held, promotes an “open access” business model, by which it partners with other companies to develop and improve its core technology without upfront contract fees, milestone payments or royalty fees

GNF director Peter Schultz said in a statement that the institute, also based in San Diego, plans to use the product in its forward mouse genetics research program.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.